Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial.

Giovanni Fernando TorelliSabina ChiarettiNadia PeragineWalter BarberiLaura SantodonatoGiuseppina D'AgostinoElisabetta AbruzzeseMaria Ilaria Del PrincipeAlessandra MancinoMabel MatarazzoMahnaz Shafii BaftiMarco ManciniMonica MessinaLuciano CastielloAnna GuariniRobin Foà

Published in: American journal of hematology (2022)

Keyphrases

acute lymphoblastic leukemia
natural killer cells
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
bone marrow
prognostic factors
peritoneal dialysis
allogeneic hematopoietic stem cell transplantation
cell therapy